ArticleMedicine2024
Construction of a prognostic risk model for uveal melanoma based on immune-related long noncoding RNA.
Article in Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pointmaps to Practice: 3D Multi-view Ocular Lesion Mapping.Journal of imaging informatics in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanoma (UM) is a common health challenge worldwide as a prevalent intraocular malignancy because of its high mortality rate. However, clinical workers do not have an accurate prognostic tool now. Immune function is closely related to tumor development. Interestingly, researchers have identified that long noncoding RNAs (lncRNAs) are tightly associated with biological processes at the cellular level, particularly their involvements in immune response and its regulation of the growth of tumor cells. Hence, lncRNAs may be involved in the progression of uveal melanoma. UM patients' RNA expression matrices were extracted from TCGA database. The targeted immune genes were filtered by weighted correlation network analysis and the immune-related lncRNAs with a high prognostic relevance were obtained by Cox regression analysis and least absolute shrinkage and selection operator regression analysis. Each sample was scored according to those lncRNA expression and divided into high-risk and low-risk group. We confirmed the sensitivity and independence of our risk model compared to the tumor mutation burden score. Finally, we demonstrated the clinical relevance of our model by examining its sensitivity to different drugs. The risk score based on our risk model was significantly independent of other clinical parameters in either univariate (hazard ratio = 109.852 [15.738-766.749], P value < .001) or multivariate (hazard ratio = 114.075 [15.207-855.735], P value < .001) analyses. The ROC curves of this model imply high predictive accuracy for 1-year, 3-year, and 5-year survival (1-year area under the curve [AUC] = 0.849, 3-years AUC = 0.848, and 5-years AUC = 0.761). Our study revealed that immune-related lncRNAs are significant in the clinical diagnosis, treatment and prognosis of UM patients. We successfully constructed a lncRNA-based prognostic risk model which may serve as a future reference for the diagnosis and prognosis of UM. Based on this model we also validated the sensitivity of some cancer drugs, which has implications for the future immunotherapy and drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.